BACKGROUnD AnD OBJECTivE: Older generation phacoemulsification units are widel y employed where economics do not permit frequent upgrades. Thermal effects on t he cornea while performing phacoemulsification with diffe...
详细信息
BACKGROUnD AnD OBJECTivE: Older generation phacoemulsification units are widel y employed where economics do not permit frequent upgrades. Thermal effects on t he cornea while performing phacoemulsification with different generation machine s were evaluated. PATIEnTS AnD METHODS: The thermal effect on the clear corneal incision during uncomplicated phacoemulsification performed by the Series 10,000 (Alcon Laboratories, Fort Worth, TX) and the Diplomax (Allergan, Irvine, CA) ma chines was clinically evaluated and correlated with the effective phacoemulsific ation time required. The clinical outcome was analyzed with respect to wound clo sure and surgically induced corneal astigmatism. RESULTS: The average effective phacoemulsification time required to emulsify a grade iv cataract was 88.33 ±15 .81 seconds with the Series 10,000 machine and 61.67 ±21.79 seconds with the Di plomax machine. A grade 2 or more thermal effect was seen in 19.33%of patients operated on with the Series 10,000 machine and 3.22%of patients operated on wit h the Diplomax machine. The resultant tissue retraction affected wound closure a nd mean surgically induced corneal astigmatism (1.71 ±1.05 D with the Diplomax machine and 2.21 ±1.32 D with the Series 10,000 machine). COnCLUSIOnS: newer ge neration machines require less phacoemulsification power to emulsify hard catara cts, and the clinical outcomes are more favorable. Incision burns must be kept i n mind when working with older generation phacoemulsification machines.
Background The prognosis of patients with recurrent World Health Organization(WHO)grade iv malignant glioma is dismal,and there is currently no effective *** conducted a dose-finding and toxicity study in this populat...
详细信息
Background The prognosis of patients with recurrent World Health Organization(WHO)grade iv malignant glioma is dismal,and there is currently no effective *** conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor *** We enrolled consecutive adult patients who had recurrent supratentorial WHO grade iv malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion *** From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of *** level-1(5.0×107TCID50)was identified as the phase 2 *** dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was *** mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 *** the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or *** survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 *** Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade iv malignant glioma confirmed the absence of neurovirulent *** survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls.
暂无评论